Protiveris, Inc. Moves Into Larger Facility, Expands R&D And Manufacturing Capability 
10/19/2005 5:10:12 PM

ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Protiveris Inc., a bio- nanotechnology company commercializing proprietary bioMEMS technologies to facilitate protein research and the discovery of new pharmaceuticals, today announced their completed move to a larger, state-of-the-art facility with greater R&D and manufacturing capabilities. Protiveris is leasing approximately 7,000 sq. ft. of space with office suites and fully functional laboratories for chemistry, biology, engineering, manufacturing and production. The new location at 15010 Broschart Road is situated in the heart of Rockville's biotechnology corridor.

"This new location is ideal for our current stage of development," said Robert Menzi, Chief Operating Officer. "We now have the capacity to more than double in size and pursue manufacturing and development well into our product's lifecycle."

Since its founding in 2000, Protiveris has occupied space in the Maryland Technology Development Center (MTDC) Incubator in Rockville, MD. The move to a larger facility was partially funded by the completion of a $5 million venture capital financing round in the spring of 2003.

"MTDC is a fantastic launching pad for early-stage technology and biotechnology companies," said Sebastian Kossek, PhD, Chief Science Officer. "In the last year, after achieving several development milestones and raising additional capital, we realized that the transition to a new environment capable of sustaining that growth was in order. We expect to enter the manufacturing stage of our VeriScan(TM) 3000 system within the next 12 months, and this new site is well suited for that stage of development."

About Protiveris, Inc.

Protiveris is committed to advancing traditional laboratory experimentation by establishing the standard of performance for proteomic research tools. The VeriScan(TM) 3000 bench top protein biochip system, developed using proprietary microcantilever technology, detects biomolecular and chemical interactions to enable more efficient and accurate protein research outcomes. The microfluidic protein biochip and optical reader utilize arrays of microcantilevers with customizable surfaces to measure interactions between proteins, antibodies, antigens, or DNA. This system offers label-free detection at concentrations several orders of magnitude lower than existing techniques and provides researchers with the ability to create high content assays that deliver real time data. More information about Protiveris, their technology, products, and services can be found at the company's web site at

Protiveris, Inc.

CONTACT: Robert Menzi, Chief Operating Officer, of Protiveris Inc.,+1-301-738-7800,